Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 6/2018

28.08.2018 | Glycogen Storage Disease

Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study

verfasst von: Claudio Semplicini, Pascaline Letard, Marie De Antonio, Nadjib Taouagh, Barbara Perniconi, Françoise Bouhour, Andoni Echaniz-Laguna, David Orlikowski, Sabrina Sacconi, Emmanuelle Salort-Campana, Guilhem Solé, Fabien Zagnoli, Dalil Hamroun, Roseline Froissart, Catherine Caillaud, Pascal Laforêt, French Pompe Study Group

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Pompe disease (PD) is caused by a deficiency of lysosomal acid α-glucosidase resulting from mutations in the GAA gene. The clinical spectrum ranges from a rapidly fatal multisystemic disorder (classic PD, onset < 1 year) to a milder adult onset myopathy. The aims of this study were to characterize the GAA mutations, to establish the disease epidemiology, and to identify potential genotype-phenotype correlations in French late-onset PD patients (onset ≥ 2 years) diagnosed since the 1970s. Data were collected from the two main laboratories involved in PD diagnosis and from the French Pompe registry. Two hundred forty-six patients (130 females and 116 males) were included, with a mean age at diagnosis of 43 years. Eighty-three different mutations were identified in the GAA gene, among which 28 were novel. These variants were spread all over the sequence and included 42 missense (one affecting start codon), 8 nonsense, 15 frameshift, 14 splice mutations, 3 small in-frame deletions, and one large deletion. The common c.-32-13T>G mutation was detected in 151/170 index cases. Other frequent mutations included the exon 18 deletion, the c.525del, and the missense mutations c.1927G>A (p.Gly643Arg) and c.655G>A (p.Gly219Arg). Patients carrying the c.-32-13T>G mutation had an older mean age at onset than patients non-exhibiting this mutation (36 versus 25 years). Patients with the same genotype had a highly variable age at onset. We estimated the frequency of late-onset PD in France around 1/69,927 newborns. In conclusion, we characterized the French cohort of late-onset PD patients through a nationwide study covering more than 40 years.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Angelini C, Semplicini C, Ravaglia S et al (2012) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 259:952–958CrossRefPubMed Angelini C, Semplicini C, Ravaglia S et al (2012) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 259:952–958CrossRefPubMed
Zurück zum Zitat Ausems MG, Verbiest J, Hermans MP et al (1999) Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 7:713–716CrossRefPubMed Ausems MG, Verbiest J, Hermans MP et al (1999) Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 7:713–716CrossRefPubMed
Zurück zum Zitat Ausems MG, ten Berg K, Sandkuijl LA et al (2001) Dutch patients with glycogen storage disease type II show common ancestry for the 525delT and del exon 18 mutations. J Med Genet 38:527–529CrossRefPubMedPubMedCentral Ausems MG, ten Berg K, Sandkuijl LA et al (2001) Dutch patients with glycogen storage disease type II show common ancestry for the 525delT and del exon 18 mutations. J Med Genet 38:527–529CrossRefPubMedPubMedCentral
Zurück zum Zitat Bodamer OA, Scott CR, Giugliani R, Pompe Disease Newborn Screening Working Group (2017) Newborn screening for Pompe disease. Pediatrics 140:S4–S13CrossRefPubMed Bodamer OA, Scott CR, Giugliani R, Pompe Disease Newborn Screening Working Group (2017) Newborn screening for Pompe disease. Pediatrics 140:S4–S13CrossRefPubMed
Zurück zum Zitat Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, Case LE, Jones HN, Kishnani PS (2017) The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab 120:163–172CrossRefPubMed Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, Case LE, Jones HN, Kishnani PS (2017) The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab 120:163–172CrossRefPubMed
Zurück zum Zitat Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL (2011) Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr 158:1023–1027CrossRefPubMed Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL (2011) Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr 158:1023–1027CrossRefPubMed
Zurück zum Zitat Dardis A, Zanin I, Zampieri S et al (2014) Functional characterization of the common c.-32-13T>G mutation of GAA gene: identification of potential therapeutic agents. Nucleic Acids Res 42:1291–1302CrossRefPubMed Dardis A, Zanin I, Zampieri S et al (2014) Functional characterization of the common c.-32-13T>G mutation of GAA gene: identification of potential therapeutic agents. Nucleic Acids Res 42:1291–1302CrossRefPubMed
Zurück zum Zitat Echaniz-Laguna A, Carlier RY, Laloui K et al (2015) Should patients with asymptomatic Pompe disease be treated? A nationwide study in France. Muscle Nerve 51:884–889CrossRefPubMed Echaniz-Laguna A, Carlier RY, Laloui K et al (2015) Should patients with asymptomatic Pompe disease be treated? A nationwide study in France. Muscle Nerve 51:884–889CrossRefPubMed
Zurück zum Zitat Güngör D, Reuser AJ (2013) How to describe the clinical spectrum in Pompe disease? Am J Med Genet A 161A:399–400CrossRefPubMed Güngör D, Reuser AJ (2013) How to describe the clinical spectrum in Pompe disease? Am J Med Genet A 161A:399–400CrossRefPubMed
Zurück zum Zitat Hagemans ML, Winkel LP, Van Doorn PA et al (2005) Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain 128:671–677CrossRefPubMed Hagemans ML, Winkel LP, Van Doorn PA et al (2005) Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain 128:671–677CrossRefPubMed
Zurück zum Zitat Hagemans ML, Hop WJ, Van Doorn PA, Reuser AJ, van der Ploeg AT (2006) Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology 66:581–583CrossRefPubMed Hagemans ML, Hop WJ, Van Doorn PA, Reuser AJ, van der Ploeg AT (2006) Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology 66:581–583CrossRefPubMed
Zurück zum Zitat Herzog A, Hartung R, Reuser AJ et al (2012) A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations. Orphanet J Rare Dis 7:35CrossRefPubMedPubMedCentral Herzog A, Hartung R, Reuser AJ et al (2012) A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations. Orphanet J Rare Dis 7:35CrossRefPubMedPubMedCentral
Zurück zum Zitat Hirschhorn R, Huie ML (1999) Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally “common” in white populations. J Med Genet 36:85–86PubMedPubMedCentral Hirschhorn R, Huie ML (1999) Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally “common” in white populations. J Med Genet 36:85–86PubMedPubMedCentral
Zurück zum Zitat Hirschhorn R, Reuser AJ (2001) Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver C, Baudet A, Sly et al (eds) The metabolic and molecular bases of inherited diseases. McGraw-Hill, New York, pp 3389–3420 Hirschhorn R, Reuser AJ (2001) Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver C, Baudet A, Sly et al (eds) The metabolic and molecular bases of inherited diseases. McGraw-Hill, New York, pp 3389–3420
Zurück zum Zitat Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJ, Oostra BA (1990) Characterization of the human lysosomal alpha-glucosidase gene. Biochem J 272:493–497CrossRefPubMedPubMedCentral Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJ, Oostra BA (1990) Characterization of the human lysosomal alpha-glucosidase gene. Biochem J 272:493–497CrossRefPubMedPubMedCentral
Zurück zum Zitat Huie ML, Chen AS, Tsujino S et al (1994) Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T>G) mutation in a majority of patients and a novel IVS10 (+1GT>CT) mutation. Hum Mol Genet 3:2231–2236CrossRefPubMed Huie ML, Chen AS, Tsujino S et al (1994) Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T>G) mutation in a majority of patients and a novel IVS10 (+1GT>CT) mutation. Hum Mol Genet 3:2231–2236CrossRefPubMed
Zurück zum Zitat Kishnani PS, Hwu WL, Mandel H et al (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671–676CrossRefPubMed Kishnani PS, Hwu WL, Mandel H et al (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671–676CrossRefPubMed
Zurück zum Zitat Kishnani PS, Amartino HM, Lindberg C et al (2013) Timing of diagnosis of patients with Pompe disease: data from the Pompe registry. Am J Med Genet A 161A:2431–2443PubMed Kishnani PS, Amartino HM, Lindberg C et al (2013) Timing of diagnosis of patients with Pompe disease: data from the Pompe registry. Am J Med Genet A 161A:2431–2443PubMed
Zurück zum Zitat Kroos MA, Van der Kraan M, Van Diggelen OP et al (1995) Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet 32:836–837CrossRefPubMedPubMedCentral Kroos MA, Van der Kraan M, Van Diggelen OP et al (1995) Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet 32:836–837CrossRefPubMedPubMedCentral
Zurück zum Zitat Kroos MA, Pomponio RJ, Hagemans ML et al (2007) Broad spectrum of Pompe disease in patients with the same c.-32-13T>G haplotype. Neurology 68:110–115CrossRefPubMed Kroos MA, Pomponio RJ, Hagemans ML et al (2007) Broad spectrum of Pompe disease in patients with the same c.-32-13T>G haplotype. Neurology 68:110–115CrossRefPubMed
Zurück zum Zitat Kroos M, Pomponio RJ, van Vliet L et al (2008) Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat 29:E13–E26CrossRefPubMed Kroos M, Pomponio RJ, van Vliet L et al (2008) Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat 29:E13–E26CrossRefPubMed
Zurück zum Zitat Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ (2012) The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 160C:59–68CrossRefPubMed Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ (2012) The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 160C:59–68CrossRefPubMed
Zurück zum Zitat Laforet P, Nicolino M, Eymard PB et al (2000) Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 55:1122–1128CrossRefPubMed Laforet P, Nicolino M, Eymard PB et al (2000) Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 55:1122–1128CrossRefPubMed
Zurück zum Zitat Laforêt P, Laloui K, Granger B et al (2013) The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease. Rev Neurol 169:595–602CrossRefPubMed Laforêt P, Laloui K, Granger B et al (2013) The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease. Rev Neurol 169:595–602CrossRefPubMed
Zurück zum Zitat Leslie N, Bailey L (2007) Pompe disease. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews®.Seattle (WA). University of Washington, Seattle, pp 1993–2018 Leslie N, Bailey L (2007) Pompe disease. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews®.Seattle (WA). University of Washington, Seattle, pp 1993–2018
Zurück zum Zitat Martiniuk F, Chen A, Mack A et al (1998) Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 79:69–72CrossRefPubMed Martiniuk F, Chen A, Mack A et al (1998) Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 79:69–72CrossRefPubMed
Zurück zum Zitat Montalvo AL, Bembi B, Donnarumma M et al (2006) Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat 27:999–1006CrossRefPubMed Montalvo AL, Bembi B, Donnarumma M et al (2006) Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat 27:999–1006CrossRefPubMed
Zurück zum Zitat Palmer RE, Amartino HM, Niizawa G, Blanco M, Pomponio RJ, Chamoles NA (2007) Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations. Neuromuscul Disord 17:16–22CrossRefPubMed Palmer RE, Amartino HM, Niizawa G, Blanco M, Pomponio RJ, Chamoles NA (2007) Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations. Neuromuscul Disord 17:16–22CrossRefPubMed
Zurück zum Zitat Pompe Disease Diagnostic Working Group, Winchester B, Bali D et al (2008) Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab 93:275–281CrossRef Pompe Disease Diagnostic Working Group, Winchester B, Bali D et al (2008) Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab 93:275–281CrossRef
Zurück zum Zitat Raben N, Nichols RC, Martiniuk F, Plotz PH (1996) A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II). Hum Mol Genet 5:995–1000CrossRefPubMed Raben N, Nichols RC, Martiniuk F, Plotz PH (1996) A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II). Hum Mol Genet 5:995–1000CrossRefPubMed
Zurück zum Zitat Rairikar MV, Case LE, Bailey LA et al (2017) Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G “late-onset” GAA variant. Mol Genet Metab 122:99–107CrossRefPubMedPubMedCentral Rairikar MV, Case LE, Bailey LA et al (2017) Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G “late-onset” GAA variant. Mol Genet Metab 122:99–107CrossRefPubMedPubMedCentral
Zurück zum Zitat Remiche G, Ronchi D, Magri F et al (2014) Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature. J Neurol 261:83–97CrossRefPubMed Remiche G, Ronchi D, Magri F et al (2014) Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature. J Neurol 261:83–97CrossRefPubMed
Zurück zum Zitat Reuser AJ, Verheijen FW, Bali D et al (2011) The use of dried blood spot samples in the diagnosis of lysosomal storage disorders - current status and perspectives. Mol Genet Metab 104:144–148CrossRefPubMed Reuser AJ, Verheijen FW, Bali D et al (2011) The use of dried blood spot samples in the diagnosis of lysosomal storage disorders - current status and perspectives. Mol Genet Metab 104:144–148CrossRefPubMed
Zurück zum Zitat Strothotte S, Strigl-Pill N, Grunert B et al (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91–97CrossRefPubMed Strothotte S, Strigl-Pill N, Grunert B et al (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91–97CrossRefPubMed
Zurück zum Zitat van der Ploeg AT, Clemens PR, Corzo D et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362:1396–1406CrossRefPubMed van der Ploeg AT, Clemens PR, Corzo D et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362:1396–1406CrossRefPubMed
Zurück zum Zitat Winkel LP, Hagemans ML, van Doorn PA et al (2005) The natural course of non–classic Pompe’s disease; a review of 225 published cases. J Neurol 252:875–884CrossRefPubMed Winkel LP, Hagemans ML, van Doorn PA et al (2005) The natural course of non–classic Pompe’s disease; a review of 225 published cases. J Neurol 252:875–884CrossRefPubMed
Metadaten
Titel
Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study
verfasst von
Claudio Semplicini
Pascaline Letard
Marie De Antonio
Nadjib Taouagh
Barbara Perniconi
Françoise Bouhour
Andoni Echaniz-Laguna
David Orlikowski
Sabrina Sacconi
Emmanuelle Salort-Campana
Guilhem Solé
Fabien Zagnoli
Dalil Hamroun
Roseline Froissart
Catherine Caillaud
Pascal Laforêt
French Pompe Study Group
Publikationsdatum
28.08.2018
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 6/2018
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-018-0243-7

Weitere Artikel der Ausgabe 6/2018

Journal of Inherited Metabolic Disease 6/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.